• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Therapeutic plasmapheresis in patients with multiple myeloma].

作者信息

Mendek-Czajkowska E, Kraj M, Pogłód R, Rostkowska J, Maj S, Sabliński J

机构信息

Kliniki Hematologicznej Instytutu Hematologii, Warszawie.

出版信息

Acta Haematol Pol. 1991;22(1):31-41.

PMID:1823964
Abstract

The effectiveness of therapeutic plasmaphereses with antineoplastic chemotherapy was evaluated in 25 cases of plasmocytic myeloma in stage III of progression of the proliferative process. The indication to plasmapheresis was hypergelification of serum with clinical symptoms of central nervous system disturbances, renal failure in various stages of progression, intensification of coronary symptoms, bleeding tendency. Good effects with reduced level of total protein and monoclonal protein in serum by 30-80% with regression of clinical symptoms caused by serum hypergelification were obtained in 11 cases. In the remaining patients clinical improvement of varying degree was noted when the level of total and monoclonal protein in the serum fell by 10-29%.

摘要

相似文献

1
[Therapeutic plasmapheresis in patients with multiple myeloma].
Acta Haematol Pol. 1991;22(1):31-41.
2
[Clinical and laboratory analysis of the cases of multiple myeloma with over 5-year survival time from the beginning of the antineoplastic treatment].[抗肿瘤治疗开始后生存时间超过5年的多发性骨髓瘤病例的临床与实验室分析]
Acta Haematol Pol. 1991;22(1):42-7.
3
[Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].[采用美法仑、泼尼松、环磷酰胺、长春新碱和卡氮芥治疗II期和III期多发性骨髓瘤(M-2方案)]
Rev Clin Esp. 1985 May;176(8):392-5.
4
[Plasmocytic pleural effusion disclosing multiple myeloma].[浆细胞性胸腔积液揭示多发性骨髓瘤]
Rev Mal Respir. 2000 Apr;17(2):495-7.
5
Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Cancer Treat Rep. 1984 Dec;68(12):1439-46.
6
[Chemotherapy and immunomodulating treatment of patients with multiple myeloma].
Acta Haematol Pol. 1991;22(1):4-20.
7
Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.早期收获和晚期移植作为多发性骨髓瘤的一种有效治疗策略。
Bone Marrow Transplant. 1999 Feb;23(3):221-6. doi: 10.1038/sj.bmt.1701559.
8
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.美法仑和泼尼松联合长春新碱、卡莫司汀、美法仑、环磷酰胺及泼尼松治疗多发性骨髓瘤的比较:东部肿瘤协作组E2479研究结果
Cancer. 1997 Apr 15;79(8):1561-7.
9
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.在多发性骨髓瘤患者治疗中,于标准化疗基础上加用干扰素或大剂量环磷酰胺:东部肿瘤协作组III期临床试验EST 9486
Cancer. 1999 Sep 15;86(6):957-68.
10
[Acute ischemia and heart failure during cyclic chemotherapy in a patient with plasmocytic myeloma].[浆细胞性骨髓瘤患者周期性化疗期间的急性缺血与心力衰竭]
Pol Tyg Lek. 1990;45(51-52):1056-8.